Research
Hormonal
Once-weekly insulin icodec provides glycemic control similar to once-daily insulin glargine with comparable hypoglycemia rates, potentially improving patient acceptability through reduced injection frequency.
If daily injections are burdensome, ask your doctor about once-weekly insulin icodec. It works as well as daily insulin for blood sugar control and has similar side effects, but offers the convenience of fewer injections.
GoodSupportsHIGH confidence
Once-weekly insulin icodec was compared with once-daily insulin glargine U100 with 2–4 daily bolus insulin aspart injections in 582 persons with type 2 diabetes treated for 26 weeks, finding similar 1.2% reductions in HbA1c from 8.3% baseline... and similar 37% vs 45% rates of level 1 hypoglycemia and 19% vs 25% rates of level 2 or 3 hypoglycemia.
Why this rating
Based on phase 3a randomized controlled trial.
Source
A diabetes update
Zachary T. Bloomgarden · Journal of Diabetes · 2023
DOI 10.1111/1753-0407.13434
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intensive blood pressure control (target <130/80 mmHg) reduces stroke and macroalbuminuria progression in type 2 diabetes compared to conventional control, without significantly affecting all-cause mortality.Strong
- GLP-1 receptor agonists (e.g., tirzepatide, danuglipron) produce significant weight loss and glycemic improvement in type 2 diabetes and obesity, with weight loss and glycemic effects being partially independent mechanisms.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →